Comparison of Two Formulations of Proellex for Oral Administration

A Double-Blind Crossover Study in Healthy Volunteers to Compare Two Formulations of Proellex for Oral Administration

This study is a double-blind crossover study in female healthy volunteers to compare the pharmacokinetics and safety of a single dose each of two different formulations of Proellex for oral administration. Each formulation will be designated as either Treatment A or Treatment B. A total of 12 subjects who meet the eligibility criteria will be randomized to receive either Treatment A or Treatment B as their first assigned treatment. After a 7-day washout period subjects will receive the alternative treatment. On the day of each treatment subjects will remain in the clinic overnight and undergo 72-hour pharmacokinetic assessment at the following time points: 0, 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48 and 72 hours after administration of study drug.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: Telapristone Acetate, Proellex 12 mg Formulation A; Drug: Telapristone Acetate, Proellex 12 mg Formulation B

• Study Type: Interventional
• Enrollment (Actual): 12
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Texas
    • Houston, Texas, United States, 77030

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 47 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

1. Speak, read, and understand English or Spanish and is willing and able to provide written informed consent on an IRB-approved form prior to the initiation of any study procedures;
2. Healthy, premenopausal female age 18-47;
3. History of menstrual events that occur in regular cycles
4. Agreement not to attempt to become pregnant
5. Agrees to use double-barrier contraception during the study and for 30 days after discontinuation of study medication. Acceptable double-barrier methods are: male condom with spermicide; male condom with diaphragm; diaphragm containing spermicide plus additional intra-vaginal spermicide;
6. Has a negative pregnancy test at the Screening visit. An exception for the pregnancy test requirement will be granted for subjects reporting surgical sterilization in medical history
7. Normal laboratory values or clinically insignificant findings at screening as determined by the Investigator;
8. Subject is willing to remain in the clinic overnight for PK assessment on Days 0 and 8
9. Ability to complete the study procedures in compliance with the protocol.

Exclusion Criteria:

1. Subject is a post-menopausal woman, defined as either; six (6) months or more (immediately prior to screening visit) without a menstrual period, or prior hysterectomy and/or oophorectomy
2. Subject is pregnant or lactating or is attempting or expecting to become pregnant during the study
3. Women with abnormally high liver enzymes or liver disease. (ALT or AST exceeding 2.0 x ULN AND total bilirubin exceeding 1.5 x ULN at screening and confirmed on repeat).
4. Received an investigational drug in the 30 days prior to the screening for this study
5. Women with a history of PCOS
6. Concurrent use of any testosterone, progestin, androgen, estrogen, anabolic steroids, DHEA or hormonal products for at least 2 weeks prior to screening and during the study.
7. Use of oral contraceptives in the preceding 2 weeks. Use of Depo-Provera® in the preceding 10 months.
8. Has an IUD in place
9. Women currently using narcotics
10. Women currently taking spironolactone
11. Infectious disease screen is positive for HIV or Hepatitis A, B or C.
12. Clinically significant abnormal findings on screening examination or any condition which in the opinion of the investigator would interfere with the participant's ability to comply with the study instructions or endanger the participant if she took part in the study

Study Plan

How is the study designed?

Design Details

• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Telapristone Acetate, Proellex Formulation A (Treatment A); Subjects who meet the eligibility criteria will be randomized to receive either 12 mg Treatment A or 12 mg Treatment B as their first assigned treatment. After a 7-day washout period subjects will receive the alternative treatment.	Drug: Telapristone Acetate, Proellex 12 mg Formulation A; Other Names: Proellex; Drug: Telapristone Acetate, Proellex 12 mg Formulation B; Other Names: Proellex
Experimental: Telapristone Acetate, Proellex Formulation B (Treatment B); Subjects who meet the eligibility criteria will be randomized to receive either 12 mg Treatment A or 12 mg Treatment B as their first assigned treatment. After a 7-day washout period subjects will receive the alternative treatment.	Drug: Telapristone Acetate, Proellex 12 mg Formulation A; Other Names: Proellex; Drug: Telapristone Acetate, Proellex 12 mg Formulation B; Other Names: Proellex

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetic Comparison	To determine and compare the pharmacokinetics (PK) of a single dose of each of two formulations of 12 mg Proellex administered orally to female healthy volunteers. On the day of each treatment subjects will remain in the clinic overnight and undergo 72-hour pharmacokinetic assessment at the following time points: 0, 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48 and 72 hours after administration of study drug. Pharmacokinetic Endpoints; AUC 0-t; AUC 0-24; AUC 0-∞; Cmax; Tmax; λz; t½	Up to 2 weeks
Dose formulation safety	To determine and compare the safety of a single dose of each of two formulations of 12 mg Proellex administered orally to female healthy volunteers. After the completion of the study; incidence of adverse events, mean change from baseline of laboratory values (hematology, blood chemistry, urinalysis), mean change from baseline of vital signs will be assessed. Vital signs and adverse events will be recorded at each visit.	Up to 2 weeks

Collaborators and Investigators

• Sponsor: Repros Therapeutics Inc.

Study record dates

Study Major Dates

• Study Start: May 1, 2014
• Primary Completion (Actual): June 1, 2014
• Study Completion (Actual): June 1, 2014

Study Registration Dates

• First Submitted: May 13, 2014
• First Submitted That Met QC Criteria: May 14, 2014
• First Posted (Estimate): May 19, 2014

Study Record Updates

• Last Update Posted (Estimate): September 3, 2014
• Last Update Submitted That Met QC Criteria: September 2, 2014
• Last Verified: September 1, 2014

More Information

Terms related to this study

• Other Study ID Numbers: ZPU-101